Long-Term Outcomes of Coronary and Carotid Artery Disease Revascularization in the FRIENDS Study

Table 6

Propensity-adjusted three-group comparison for the primary and secondary endpoints.

	Surgical	Endovascular	Hybrid	Surgical vs. Endovascular	Surgical vs. Hybrid	Endovascular vs. Hybrid	P value
	Event rates, n (%)			HR (95% CI)
Any death	14 (14%)	18 (18%)	17 (17%)	0.9 (0.4-1.8)	0.9 (0.5-1.8)	1.1 (0.6-2.2)	.920
Non CV death	9 (9%)	8 (8%)	11 (11%)	1.2 (0.5-3.1)	0.9 (0.4-2.4)	0.8 (0.3-2.0)	.872
CV death	5 (5%)	10 (10%)	6 (6%)	0.6 (0.2-1.7)	0.9 (0.3-2.8)	1.6 (0.6-4.5)	.499
MI	7 (7%)	4 (4%)	11 (11%)	1.9 (0.7-5.3)	0.7 (0.2-2.0)	0.4 (0.1-1.1)	.193
Stroke	2 (2%)	3 (3%)	3 (3%)	0.8 (0.1-4.1)	0.6 (0.1-3.7)	0.8 (0.2-4.4)	.885
CKD/haemodialysis	6 (6%)	6 (6%)	14 (14%)	1.0 (0.4-2.7)	0.5 (0.2-1.2)	0.5 (0.2-1.2)	.093
MACCE	13 (13%)	15 (15%)	16 (16%)	1.0 (0.5-2.1)	0.9 (0.4-1.9)	0.9 (0.4-1.8)	.946
All events	24 (24%)	26 (26%)	30 (30%)	0.9 (0.5-1.6)	0.9 (0.5-1.5)	0.8 (0.5-1.4)	.690

CKD=chronic kidney disease; CV=cardiovascular; MACCE=Major Adverse Cardiac and Cerebrovascular Events; MI= myocardial infarction.